Benjamin Tomlinson: Clinical Trials

3 trials sponsored by Benjamin Tomlinson, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 recruiting. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Active not recruiting 2, Recruiting 1
Phase 21Recruiting 1

Follow Benjamin Tomlinson: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Venetoclax, Decitabine - Myeloid Malignancy, Acute Myeloid Leukemia
Phase 1 / Phase 2RecruitingBenjamin Tomlinson202025-07-282026-10-08
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Cyclophosphamide - Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Phase 1Active not recruitingBenjamin Tomlinson182021-04-262026-09-23
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Cyclophosphamide, Fludarabine, CAR-T Cells - Non-Hodgkin Lymphoma
Phase 1Active not recruitingBenjamin Tomlinson312018-07-092026-02-27

Conditions studied

Lymphoma, Non-Hodgkin (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Interventions

Cyclophosphamide (2)  ·  fludarabine (2)  ·  fludarabine phosphate (2)  ·  Decitabine (1)  ·  Immunotherapy, Adoptive (1)  ·  venetoclax (1)

Countries

United States (3)

Top investigators

Claudio Brunstein, MD, PhD (1)  ·  James Ignatz-Hoover, MD, PhD (1)

Results publications

PMID 34893603, PMID 40115173